Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib vs Erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.
Articolo
Data di Pubblicazione:
2015
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Scagliotti, G; Von Pawel, J; Novello, S; Ramlau, R; Favaretto, A; Barlesi, F; Akerley, W; Orlov, S; Santoro, A; Spigel, D; Hirsch, V; Sheperd, V A; Sequist, L V; Sandler, A; Ross, J S; Wang, Q; von Roemeling, R; Shuster, D; Schwartz, B
Link alla scheda completa:
Link al Full Text:
Pubblicato in: